Akebia Therapeutics Inc AKBA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on Dialysis
-
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Akebia Therapeutics to Present at Upcoming Investor Conferences
-
Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
-
Akebia Therapeutics to Report Second Quarter 2024 Financial Results and Discuss Recent Business Highlights
-
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Akebia Therapeutics to Present at Upcoming Investor Conferences
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.52
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 167
- Website
- https://www.akebia.com
Comparables
Valuation
Metric
|
AKBA
|
TVTX
|
AVIR
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 70.01 | 0.60 |
Price/Sales | 1.52 | 6.00 | — |
Price/Cash Flow | 25.97 | — | — |
Price/Earnings
AKBA
TVTX
AVIR
Financial Strength
Metric
|
AKBA
|
TVTX
|
AVIR
|
---|---|---|---|
Quick Ratio | 0.65 | 2.89 | 18.87 |
Current Ratio | 1.04 | 3.04 | 19.02 |
Interest Coverage | −4.41 | −35.20 | — |
Quick Ratio
AKBA
TVTX
AVIR
Profitability
Metric
|
AKBA
|
TVTX
|
AVIR
|
---|---|---|---|
Return on Assets (Normalized) | −14.83% | −9.03% | −23.62% |
Return on Equity (Normalized) | — | −47.00% | −25.11% |
Return on Invested Capital (Normalized) | −138.34% | −13.68% | −29.21% |
Return on Assets
AKBA
TVTX
AVIR
Drug Manufacturers - Specialty & Generic Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Zoetis Inc Class A
ZTS
| Lnfcyhbfr | Yyh | $87.2 Bil | |||
Merck KGaA ADR
MKKGY
| Qmlvrkgq | Hnxhjq | $75.7 Bil | |||
Haleon PLC ADR
HLN
| Zqbqxmyc | Wpxrw | $47.3 Bil | |||
Teva Pharmaceutical Industries Ltd ADR
TEVA
| Kwpqkygr | Cpfdk | $20.0 Bil | |||
Viatris Inc
VTRS
| Ctbzmcjz | Fxpt | $13.7 Bil | |||
Dr Reddy's Laboratories Ltd ADR
RDY
| Xdydhlz | Xwry | $13.4 Bil | |||
Catalent Inc
CTLT
| Pwdnqsxst | Lmfyfd | $11.0 Bil | |||
Prestige Consumer Healthcare Inc
PBH
| Fqjdgbwn | Sxngsg | $3.5 Bil | |||
Perrigo Co PLC
PRGO
| Zjntvlcg | Gllh | $3.4 Bil | |||
Green Thumb Industries Inc
GTBIF
| Yfxpllkkz | Hysk | $2.4 Bil |